STAT: Backed with $500 million, a startup aims to rethink psychiatric drug development
Read More
Archive for Neumora in the News
Endpoints: ARCH unveils its Really Big Neuroscience Company with $500M, an Amgen deal and eyes on depression, Alzheimer’s and a lot more
Read More
Business Insider: A new startup created by one of biotech’s biggest VCs shows you need to go big to treat brain disorders
Read More
Biopharma Dive: Armed with half a billion dollars, a startup aims to change how brain drugs are made
Read More
Timmerman Report: Neumora Secures $500M, Amgen Deal, in Quest for Neuroscience R&D
Read More
BioCentury: Arch-backed Neumora: using data tools for precision neuroscience
Read More
Boston Globe: Neumora hopes to bring precision medicine to brain disease treatments
Read More
Boston Business Journal: Psychiatric drug startup launches with $500M, Amgen partnership
Read More
Chemical & Engineering News: Neumora launches with $500 million to develop drugs for brain diseases
Read More
FierceBiotech: Meet Neumora, Arch’s $500M, Amgen-partnered play for the targeted future of neuroscience R&D
Read More